

Antidepressants - sCORE

Products Affected

- EMSAM PATCH 24 HOUR 12 MG/24HR TRANSDERMAL
- EMSAM PATCH 24 HOUR 6 MG/24HR TRANSDERMAL
- EMSAM PATCH 24 HOUR 9 MG/24HR TRANSDERMAL
- FETZIMA CAPSULE EXTENDED RELEASE 24 HOUR 120 MG ORAL
- FETZIMA CAPSULE EXTENDED RELEASE 24 HOUR 20 MG ORAL
- FETZIMA CAPSULE EXTENDED RELEASE 24 HOUR 40 MG ORAL
- FETZIMA CAPSULE EXTENDED RELEASE 24 HOUR 80 MG ORAL
- FETZIMA TITRATION CAPSULE ER 24 HOUR THERAPY PACK 20 & 40 MG ORAL
- SERTRALINE HCL CAPSULE 150 MG ORAL
- SERTRALINE HCL CAPSULE 200 MG ORAL
- VENLAFAXINE BESYLATE ER TABLET EXTENDED RELEASE 24 HOUR 112.5 MG ORAL

Details

Details	
Criteria	Trial of two generics of the following formulary products: bupropion, mirtazapine, citalopram, desvenlafaxine succinate ER, duloxetine, escitalopram, fluoxetine, fluvoxamine, paroxetine, sertraline (tablet or solution), venlafaxine. Approve for continuation of prior therapy.

Atypical Antipsychotics - sCORE

Products Affected

- CAPLYTA CAPSULE 10.5 MG ORAL
- CAPLYTA CAPSULE 21 MG ORAL
- CAPLYTA CAPSULE 42 MG ORAL
- FANAPT TABLET 1 MG ORAL
- FANAPT TABLET 10 MG ORAL
- FANAPT TABLET 12 MG ORAL
- FANAPT TABLET 2 MG ORAL
- FANAPT TABLET 4 MG ORAL
- FANAPT TABLET 6 MG ORAL
- FANAPT TABLET 8 MG ORAL
- FANAPT TITRATION PACK TABLET 1 & 2 & 4 & 6 MG ORAL
- LYBALVI TABLET 10-10 MG ORAL
- LYBALVI TABLET 15-10 MG ORAL
- LYBALVI TABLET 20-10 MG ORAL
- LYBALVI TABLET 5-10 MG ORAL
- VRAYLAR CAPSULE 1.5 MG ORAL
- VRAYLAR CAPSULE 3 MG ORAL
- VRAYLAR CAPSULE 4.5 MG ORAL
- VRAYLAR CAPSULE 6 MG ORAL
- VRAYLAR CAPSULE THERAPY PACK 1.5 & 3 MG ORAL

Details

Criteria	Trial of two of the following oral generic formulary atypical antipsychotic agents: aripiprazole, olanzapine, paliperidone, quetiapine, risperidone, ziprasidone. Approve for continuation of prior therapy. Step requirement does not apply for Caplyta if request is for depressive episodes associated bipolar I or II disorder.
-----------------	---

Glucagon- sCORE

Products Affected

- GLUCAGEN HYPOKIT SOLUTION
RECONSTITUTED 1 MG INJECTION

Details

Criteria	Trial of one of the following: Gvoke, Baqsimi, or Glucagon
----------	--

INHALED CORTICOSTEROID - sCORE

Products Affected

- QVAR REDIHALER AEROSOL BREATH ACTIVATED 40 MCG/ACT INHALATION
- QVAR REDIHALER AEROSOL BREATH ACTIVATED 80 MCG/ACT INHALATION

Details

Criteria	Trial of: Arnuity Ellipta and either Flovent Diskus or Flovent HFA
----------	--

Invega Hafyera Therapy - sCORE

Products Affected

- INVEGA HAFYERA SUSPENSION
PREFILLED SYRINGE 1092 MG/3.5ML
INTRAMUSCULAR
- INVEGA HAFYERA SUSPENSION
PREFILLED SYRINGE 1560 MG/5ML
INTRAMUSCULAR

Details

Criteria	Trial of one of the following: Invega Sustenna or Invega Trinza. Step applies to new starts only. Approve for continuation of prior therapy.
-----------------	--

NAMZARIC - sCORE

Products Affected

- NAMZARIC CAPSULE ER 24 HOUR THERAPY PACK 7 & 14 & 21 & 28 -10 MG ORAL
- NAMZARIC CAPSULE EXTENDED RELEASE 24 HOUR 14-10 MG ORAL
- NAMZARIC CAPSULE EXTENDED RELEASE 24 HOUR 21-10 MG ORAL
- NAMZARIC CAPSULE EXTENDED RELEASE 24 HOUR 28-10 MG ORAL
- NAMZARIC CAPSULE EXTENDED RELEASE 24 HOUR 7-10 MG ORAL

Details

Details	
Criteria	Trial of generic memantine extended-release

NON-PREFERRED SGLT2S - sCORE

Products Affected

- INVOKAMET TABLET 150-1000 MG ORAL
- INVOKAMET TABLET 150-500 MG ORAL
- INVOKAMET TABLET 50-1000 MG ORAL
- INVOKAMET TABLET 50-500 MG ORAL
- INVOKAMET XR TABLET EXTENDED RELEASE 24 HOUR 150-1000 MG ORAL
- INVOKAMET XR TABLET EXTENDED RELEASE 24 HOUR 150-500 MG ORAL
- INVOKAMET XR TABLET EXTENDED RELEASE 24 HOUR 50-1000 MG ORAL
- INVOKAMET XR TABLET EXTENDED RELEASE 24 HOUR 50-500 MG ORAL
- INVOKANA TABLET 100 MG ORAL
- INVOKANA TABLET 300 MG ORAL

Details

Details	
Criteria	Trial of Farxiga or Xigduo XR, AND one of the following: Jardiance, Synjardy, Synjardy XR. Step requirements do not apply to members with type 2 diabetes with either diabetic nephropathy or established cardiovascular disease.

PD agents - sCORE

Products Affected

- NEUPRO PATCH 24 HOUR 1 MG/24HR TRANSDERMAL
- NEUPRO PATCH 24 HOUR 2 MG/24HR TRANSDERMAL
- NEUPRO PATCH 24 HOUR 3 MG/24HR TRANSDERMAL
- NEUPRO PATCH 24 HOUR 4 MG/24HR TRANSDERMAL
- NEUPRO PATCH 24 HOUR 6 MG/24HR TRANSDERMAL
- NEUPRO PATCH 24 HOUR 8 MG/24HR TRANSDERMAL

Details

Criteria	Trial of one of the following generic formulary dopamine agonist agent: pramipexole, ropinirole
-----------------	---

RELISTOR - sCORE

Products Affected

- RELISTOR SOLUTION 12 MG/0.6ML SUBCUTANEOUS
- RELISTOR SOLUTION 12 MG/0.6ML SUBCUTANEOUS (0.6ML SYRINGE)
- RELISTOR SOLUTION 8 MG/0.4ML SUBCUTANEOUS
- RELISTOR TABLET 150 MG ORAL

Details

Criteria	Trial of lubiprostone or lactulose
-----------------	------------------------------------

RYTARY - sCORE

Products Affected

- RYTARY CAPSULE EXTENDED RELEASE 23.75-95 MG ORAL
- RYTARY CAPSULE EXTENDED RELEASE 36.25-145 MG ORAL
- RYTARY CAPSULE EXTENDED RELEASE 48.75-195 MG ORAL
- RYTARY CAPSULE EXTENDED RELEASE 61.25-245 MG ORAL

Details

Criteria	
	Trial of one generic carbidopa/levodopa containing formulation

Skin Cancer Agents - sCORE

Products Affected

- *diclofenac sodium gel 3 % external*
- PICATO GEL 0.015 % EXTERNAL
- PICATO GEL 0.05 % EXTERNAL

Details

Criteria	Trial of fluorouracil or imiquimod
-----------------	------------------------------------

Statins - sCORE

Products Affected

- LIVALO TABLET 1 MG ORAL
- LIVALO TABLET 2 MG ORAL
- LIVALO TABLET 4 MG ORAL

Details

Criteria	Trial of any one of the following generic formulary HMG-CoA reductase inhibitors (statin): atorvastatin, fluvastatin, lovastatin, pravastatin, rosuvastatin, simvastatin
-----------------	--

Index of Drugs

C

CAPLYTA CAPSULE 10.5 MG ORAL.....2
 CAPLYTA CAPSULE 21 MG ORAL.....2
 CAPLYTA CAPSULE 42 MG ORAL.....2

D

diclofenac sodium gel 3 % external..... 11

E

EMSAM PATCH 24 HOUR 12 MG/24HR
 TRANSDERMAL..... 1
 EMSAM PATCH 24 HOUR 6 MG/24HR
 TRANSDERMAL..... 1
 EMSAM PATCH 24 HOUR 9 MG/24HR
 TRANSDERMAL..... 1

F

FANAPT TABLET 1 MG ORAL.....2
 FANAPT TABLET 10 MG ORAL.....2
 FANAPT TABLET 12 MG ORAL.....2
 FANAPT TABLET 2 MG ORAL.....2
 FANAPT TABLET 4 MG ORAL.....2
 FANAPT TABLET 6 MG ORAL.....2
 FANAPT TABLET 8 MG ORAL.....2
 FANAPT TITRATION PACK TABLET 1 & 2
 & 4 & 6 MG ORAL.....2
 FETZIMA CAPSULE EXTENDED
 RELEASE 24 HOUR 120 MG ORAL..... 1
 FETZIMA CAPSULE EXTENDED
 RELEASE 24 HOUR 20 MG ORAL..... 1
 FETZIMA CAPSULE EXTENDED
 RELEASE 24 HOUR 40 MG ORAL..... 1
 FETZIMA CAPSULE EXTENDED
 RELEASE 24 HOUR 80 MG ORAL..... 1
 FETZIMA TITRATION CAPSULE ER 24
 HOUR THERAPY PACK 20 & 40 MG
 ORAL..... 1

G

GLUCAGEN HYPOKIT SOLUTION
 RECONSTITUTED 1 MG INJECTION ...3

I

INVEGA HAFYERA SUSPENSION
 PREFILLED SYRINGE 1092 MG/3.5ML
 INTRAMUSCULAR.....5
 INVEGA HAFYERA SUSPENSION
 PREFILLED SYRINGE 1560 MG/5ML
 INTRAMUSCULAR.....5
 INVOKAMET TABLET 150-1000 MG ORAL
7
 INVOKAMET TABLET 150-500 MG ORAL 7
 INVOKAMET TABLET 50-1000 MG ORAL 7
 INVOKAMET TABLET 50-500 MG ORAL..7

INVOKAMET XR TABLET EXTENDED
 RELEASE 24 HOUR 150-1000 MG
 ORAL 7

INVOKAMET XR TABLET EXTENDED
 RELEASE 24 HOUR 150-500 MG ORAL
 7

INVOKAMET XR TABLET EXTENDED
 RELEASE 24 HOUR 50-1000 MG ORAL
 7

INVOKAMET XR TABLET EXTENDED
 RELEASE 24 HOUR 50-500 MG ORAL 7

INVOKANA TABLET 100 MG ORAL..... 7

INVOKANA TABLET 300 MG ORAL..... 7

L

LIVALO TABLET 1 MG ORAL.....12

LIVALO TABLET 2 MG ORAL.....12

LIVALO TABLET 4 MG ORAL.....12

LYBALVI TABLET 10-10 MG ORAL..... 2

LYBALVI TABLET 15-10 MG ORAL..... 2

LYBALVI TABLET 20-10 MG ORAL..... 2

LYBALVI TABLET 5-10 MG ORAL..... 2

N

NAMZARIC CAPSULE ER 24 HOUR
 THERAPY PACK 7 & 14 & 21 & 28 -10
 MG ORAL..... 6

NAMZARIC CAPSULE EXTENDED
 RELEASE 24 HOUR 14-10 MG ORAL.. 6

NAMZARIC CAPSULE EXTENDED
 RELEASE 24 HOUR 21-10 MG ORAL.. 6

NAMZARIC CAPSULE EXTENDED
 RELEASE 24 HOUR 28-10 MG ORAL.. 6

NAMZARIC CAPSULE EXTENDED
 RELEASE 24 HOUR 7-10 MG ORAL.... 6

NEUPRO PATCH 24 HOUR 1 MG/24HR
 TRANSDERMAL 8

NEUPRO PATCH 24 HOUR 2 MG/24HR
 TRANSDERMAL 8

NEUPRO PATCH 24 HOUR 3 MG/24HR
 TRANSDERMAL 8

NEUPRO PATCH 24 HOUR 4 MG/24HR
 TRANSDERMAL 8

NEUPRO PATCH 24 HOUR 6 MG/24HR
 TRANSDERMAL 8

NEUPRO PATCH 24 HOUR 8 MG/24HR
 TRANSDERMAL 8

P

PICATO GEL 0.015 % EXTERNAL.....11

PICATO GEL 0.05 % EXTERNAL.....11

Formulary ID 22504 Version 17 Effective Date: 10/01/2022

Last Updated: September 2022

Q
 QVAR REDIHALER AEROSOL BREATH
 ACTIVATED 40 MCG/ACT INHALATION
4
 QVAR REDIHALER AEROSOL BREATH
 ACTIVATED 80 MCG/ACT INHALATION
4

R
 RELISTOR SOLUTION 12 MG/0.6ML
 SUBCUTANEOUS9
 RELISTOR SOLUTION 12 MG/0.6ML
 SUBCUTANEOUS (0.6ML SYRINGE) ...9
 RELISTOR SOLUTION 8 MG/0.4ML
 SUBCUTANEOUS9
 RELISTOR TABLET 150 MG ORAL9
 RYTARY CAPSULE EXTENDED RELEASE
 23.75-95 MG ORAL 10
 RYTARY CAPSULE EXTENDED RELEASE
 36.25-145 MG ORAL 10

RYTARY CAPSULE EXTENDED RELEASE
 48.75-195 MG ORAL..... 10
 RYTARY CAPSULE EXTENDED RELEASE
 61.25-245 MG ORAL..... 10

S
 SERTRALINE HCL CAPSULE 150 MG
 ORAL 1
 SERTRALINE HCL CAPSULE 200 MG
 ORAL 1

V
 VENLAFAXINE BESYLATE ER TABLET
 EXTENDED RELEASE 24 HOUR 112.5
 MG ORAL..... 1
 VRAYLAR CAPSULE 1.5 MG ORAL..... 2
 VRAYLAR CAPSULE 3 MG ORAL..... 2
 VRAYLAR CAPSULE 4.5 MG ORAL..... 2
 VRAYLAR CAPSULE 6 MG ORAL..... 2
 VRAYLAR CAPSULE THERAPY PACK 1.5
 & 3 MG ORAL 2